

Tina-quant Transferrin ver.2**Order information**

REF	CONTENT	Analyzer(s) on which cobas c pack(s) can be used
03015050 122	Tina-quant Transferrin ver.2/ 100 tests	System-ID 07 6567 8 Roche/Hitachi cobas c 311, cobas c 501/502
11355279 216	Calibrator f.a.s. Proteins (5 x 1 mL)	Code 656
11355279 160	Calibrator f.a.s. Proteins (5 x 1 mL, for USA)	Code 656
10557897 122	Precinorm Protein (3 x 1 mL)	Code 302
10557897 160	Precinorm Protein (3 x 1 mL, for USA)	Code 302
11333127 122	Precipath Protein (3 x 1 mL)	Code 303
11333127 160	Precipath Protein (3 x 1 mL, for USA)	Code 303
10171743 122	Precinorm U (20 x 5 mL)	Code 300
10171735 122	Precinorm U (4 x 5 mL)	Code 300
05117003 190	PreciControl ClinChem Multi 1 (20 x 5 mL)	Code 391
05947626 190	PreciControl ClinChem Multi 1 (4 x 5 mL)	Code 391
05947626 160	PreciControl ClinChem Multi 1 (4 x 5 mL, for USA)	Code 391
05117216 190	PreciControl ClinChem Multi 2 (20 x 5 mL)	Code 392
05947774 190	PreciControl ClinChem Multi 2 (4 x 5 mL)	Code 392
05947774 160	PreciControl ClinChem Multi 2 (4 x 5 mL, for USA)	Code 392
04489357 190	Diluent NaCl 9 % (50 mL)	System-ID 07 6869 3

English**System information**For **cobas c** 311/501 analyzers:**TRSF2:** ACN 187For **cobas c** 502 analyzer:**TRSF2:** ACN 8187**Intended use**In vitro test for the quantitative determination of transferrin in human serum and plasma on Roche/Hitachi **cobas c** systems.**Summary**^{1,2,3,4,5}

Transferrin is a glycoprotein with a molecular weight of 79570 daltons. It consists of a polypeptide strand with two N-glycosidically linked oligosaccharide chains and exists in numerous isoforms. The rate of synthesis in the liver can be altered in accordance with the body's iron requirements and iron reserves.

Transferrin is the iron transport protein in serum. In cases of iron deficiency, the degree of transferrin saturation appears to be an extremely sensitive indicator of functional iron depletion. The ferritin levels are depressed when there is a deficiency of storage iron. In sideropenia, an iron deficiency can be excluded if the serum transferrin concentration is low, as in inflammations or - less commonly - in cases of ascorbic acid deficiency. In screening for hereditary hemochromatosis, transferrin saturation provides a better indication of the homozygous genotype than does ferritin. The treatment of anemia with erythropoietin in patients with renal failure is only effective when sufficient depot iron is present. The best monitoring procedure is to determine transferrin saturation during therapy. Transferrin saturation in conjunction with ferritin gives a conclusive prediction of the exclusion of iron overloading in patients with chronic liver disease.

A variety of methods are available for determining transferrin including radial immunodiffusion, nephelometry and turbidimetry. The Roche transferrin assay is based on the immunological agglutination principle.

Test principleImmunoturbidimetric assay.^{6,7,8}

Human transferrin forms a precipitate with a specific antiserum which is determined turbidimetrically.

Reagents - working solutions

R1 Phosphate buffer: 55 mmol/L, pH 7.2; NaCl: 25 mmol/L; polyethylene glycol: 5 %; preservative

R2 Anti-human transferrin antibodies (rabbit): dependent on titer; NaCl: 100 mmol/L; preservative

R1 is in position B and R2 is in position C.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

Reagent handling

Ready for use

Storage and stability**TRSF2**

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer:

8 weeks

Diluent NaCl 9 %

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer:

12 weeks

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable. Serum.

Plasma: Li-heparin plasma. Do not use EDTA or citrate plasma.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Stability:⁹

8 days at 15-25 °C

8 days at 2-8 °C

6 months at (-15)-(-25) °C

Materials provided

See "Reagents – working solutions" section for reagents.



Materials required (but not provided)

- See "Order information" section
- General laboratory equipment

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Application for serum and plasma

cobas c 311 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 6-25		
Wavelength (sub/main)	700 / 505 nm		
Reaction direction	Increase		
Units	g/L (µmol/L, mg/dL)		
Reagent pipetting	Diluent (H ₂ O)		
R1	140 µL	–	
R2	30 µL	–	
Sample volumes	Sample	Sample dilution	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	12.5 µL	9 µL	180 µL
Decreased	12.5 µL	5 µL	152 µL
Increased	12.5 µL	9 µL	180 µL

cobas c 501 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 10-36		
Wavelength (sub/main)	700/505 nm		
Reaction direction	Increase		
Units	g/L (µmol/L, mg/dL)		
Reagent pipetting	Diluent (H ₂ O)		
R1	140 µL	–	
R2	30 µL	–	
Sample volumes	Sample	Sample dilution	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	12.5 µL	9 µL	180 µL
Decreased	12.5 µL	5 µL	152 µL
Increased	12.5 µL	9 µL	180 µL

cobas c 502 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 10-36		
Wavelength (sub/main)	700/505 nm		
Reaction direction	Increase		
Units	g/L (µmol/L, mg/dL)		
Reagent pipetting	Diluent (H ₂ O)		
R1	140 µL	–	
R2	30 µL	–	
Sample volumes	Sample	Sample dilution	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	12.5 µL	9 µL	180 µL

Decreased	12.5 µL	5 µL	152 µL
Increased	12.5 µL	18 µL	180 µL

Calibration

Calibrators	S1: H ₂ O S2-S6: C.f.a.s. Proteins
	Multiply the lot-specific C.f.a.s. Proteins calibrator value by the factors below to determine the standard concentrations for the 6-point calibration curve:
	S2: 0.120 S5: 1.00
	S3: 0.239 S6: 1.91
	S4: 0.478
Calibration mode	RCM2
Calibration frequency	Full calibration • after reagent lot change • as required following quality control procedures

Traceability: This method has been standardized against the reference preparation of the IRMM (Institute for Reference Materials and Measurements) BCR470/CRM470 (RPPHS - Reference Preparation for Proteins in Human Serum).¹⁰

Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

Roche/Hitachi **cobas c** systems automatically calculate the analyte concentration of each sample.

Conversion factors:	mg/dL x 0.01 = g/L	g/L x 12.6 = µmol/L
	g/L x 100 = mg/dL	µmol/L x 0.0796 = g/L

Limitations - interference

Criterion: Recovery within ± 10 % of initial value at a transferrin concentration of 2 g/L (25.2 µmol/L, 200 mg/dL).

Icterus:¹¹ No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 µmol/L or 60 mg/dL).

Hemolysis:¹¹ No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 621 µmol/L or 1000 mg/dL).

Lipemia (Intralipid):¹¹ No significant interference up to an L index of 500. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Rheumatoid factors up to 1200 IU/mL do not interfere.

High dose hook-effect: No false result occurs up to a transferrin concentration of 17 g/L (214 µmol/L, 1700 mg/dL).


Drugs: No interference was found at therapeutic concentrations using common drug panels.^{12,13}

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹⁴

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. The latest version of the carry-over evasion list can be found with the NaOH/SMS/Multiclean/SCCS or the



NaOHD/SMS/SmpCln1+2/SCCS Method Sheets. For further instructions refer to the operator's manual. **cobas c 502** analyzer: All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is not required.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges

Measuring range

0.1-5.2 g/L (1.26-65.5 µmol/L, 10-520 mg/dL)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:1.5 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 1.5.

Lower limits of measurement

Lower detection limit of the test

0.1 g/L (1.26 µmol/L, 10 mg/dL)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying 3 standard deviations above that of the lowest standard (standard 1 + 3 SD, repeatability, n = 21).

Expected values¹⁵

2.0-3.6 g/L (25.2-45.4 µmol/L; 200-360 mg/dL)

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 21 days). The following results were obtained:

Repeatability	Mean	SD	CV
	g/L (µmol/L, mg/dL)	g/L (µmol/L, mg/dL)	%
Precinorm Protein	2.62 (33.0, 262)	0.03 (0.4, 3)	1.2
Precipath Protein	4.01 (50.5, 401)	0.07 (0.9, 7)	1.7
Human serum 1	1.27 (16.0, 127)	0.02 (0.3, 2)	1.2
Human serum 2	2.63 (33.1, 263)	0.04 (0.5, 4)	1.5
Intermediate precision	Mean	SD	CV
	g/L (µmol/L, mg/dL)	g/L (µmol/L, mg/dL)	%
Precinorm Protein	2.55 (32.1, 255)	0.07 (0.9, 7)	2.9
Precipath Protein	3.95 (49.8, 395)	0.13 (1.6, 13)	3.2
Human serum 3	2.14 (27.0, 214)	0.06 (0.8, 6)	2.6
Human serum 4	2.96 (37.3, 296)	0.08 (1.0, 8)	2.6

Method comparison

Transferrin values for human serum and plasma samples obtained on a Roche/Hitachi **cobas c 501** analyzer (y) were compared with those determined using the corresponding reagent on a Roche/Hitachi 917 analyzer (x).

Sample size (n) = 117

Passing/Bablok ¹⁶	Linear regression
y = 1.030x - 0.068 g/L	y = 1.018x - 0.044 g/L
τ = 0.964	r = 0.998

The sample concentrations were between 1.05 and 4.51 g/L (13.2 and 56.7 µmol/L, 105 and 450 mg/dL).

References

- Wick M, Pinggera W, Lehmann P, eds. Iron Metabolism, Diagnosis and Therapy of Anemias. 5th ed. Vienna/New York: Springer-Verlag 1999.
- Haupt H, Baudner S. Behring Inst Mitt 1990;86:16-19.
- Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial Immunodiffusion Immunochemistry 1965;2:235-243.
- Buffone GJ, Lewis SA, Josefson M, et al. Chemical and immunochemical measurement of total iron-binding capacity compared. Clin Chem 1978;24:1788-1791.
- Kreutzer HJH. An immunological turbidimetric method for serum transferrin determination. J Clin Chem Clin Biochem 1976;14:401-406.
- Lizana J, Helsing K. Manual immunonephelometric assay of proteins, with use of polymer enhancement. Clin Chem 1974;20:1181-1186.
- Tietz NW. Fundamentals of Clinical Chemistry, 2nd ed. Philadelphia, PA:WB Saunders Co 1976;278-280.
- Heidelberger M, Kendall FE. A quantitative theory of the precipitin reaction. J Exp Med 1935;62:697-720.
- Guder WG, Narayanan S, Wisser H, et al. List of Analytes; Preanalytical Variables. Brochure in: Samples: From the Patient to the Laboratory. Darmstadt: GIT-Verlag 1996.
- Baudner S, Bienvenu J, Blirup-Jensen S, et al. The certification of a matrix reference material for immunochemical measurement of 14 human serum proteins CRM470. Report EUR 15243 EN 1993;1-186.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- Schumann G, Dati F. Vorläufige Referenzbereiche für 14 Proteine im Serum (für Erwachsene) nach Standardisierung immunochemischer Methoden unter Bezug auf das internationale Referenzmaterial CRM 470. Lab Med 1995;19:401-403.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

CONTENT

Contents of kit



Volume after reconstitution or mixing

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.



0003015050122c501V7.0

TRSF2

Tina-quant Transferrin ver.2

cobas®

COBAS, COBAS C, PRECINORM, PRECIPATH, PRECICONTROL and TINA-QUANT are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Significant additions or changes are indicated by a change bar in the margin.

© 2013, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com



Distribution in USA by:

Roche Diagnostics, Indianapolis, IN

US Customer Technical Support 1-800-428-2336

